Genetic Engineering & Biotechnology News’ Post

LRRK2 in Parkinson disease: 1) LRRK2 in Parkinson disease: challenges in clinical trials (2020) https://lnkd.in/dj3tdsTQ by Eduardo Tolosa, Miquel Vila, Christine Klein & Olivier Rascol  2) LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease? (2020) https://lnkd.in/dPiekjMe by Darren O’Hara, Grishma Pawar, Suneil Kalia, Lorraine Kalia 3) Perspective on the current state of LRRK2 field (2023) https://lnkd.in/dW_4DsPC by Jean-Marc Taymans, Matthew Fell, Tim Greenamyre, Warren Hirst, Adamantios Mamais, Shalini Padmanabhan, Inga Peter, Hardy Rideout & Avner Thaler Further resources: 1. LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson’s (2020) https://lnkd.in/dCcWtfuj 2. Multiple-Hit Hypothesis in Parkinson’s Disease: LRRK2 and Inflammation (2020) 3. LRRK2 kinase in Parkinson's disease (2018) https://lnkd.in/dfM5zFit 4. Protein kinases linked to the pathogenesis of Parkinson's disease (2006) https://lnkd.in/dEXpiGg6

Did you know that Alzheimer’s and Type 2 diabetes have something in common? They both belong to a family of diseases known as amyloid diseases which are characterized by excessive protein clustering and similar early triggers. In a recent publication in the journal Protein Science, University of Washington researchers, including Valerie Daggett, AltPep’s CEO, and Steven Kahn, an AltPep scientific advisor, demonstrated that the early triggers in Type 2 diabetes are due to “alpha-sheet” structures, which have previously been implicated in Alzheimer’s disease. They also demonstrate that a synthetic polypeptide can neutralize these early triggers and work against this clustering. Check out the paper: https://lnkd.in/eiAhGuR4 Read more about this scientific work in a Q&A with Valerie Daggett published by the University of Washington below. https://lnkd.in/ezfHfcQ8 #AmyloidDiseases #AlzheimersDisease #Type2Diabetes

Nice review, Restoring mitochondrial dysfunction and dynamics, ROS reduction and epigenetic conditions are promising in the treatment of muscle disease. NAC and Q10 are also promising mitochondrial myopathies. https://lnkd.in/ej73HMHB

Study paves the way for better diagnosis and treatment of endocrine diseases . A team of researchers has discovered a new method of measuring levels of cortisol directly from a blood sample, and this marks a significant step forward in diagnosis and treatment of a wide range of diseases. #ScienceDailynews #InnovativeResearch #NextGenScience #ExploringFrontiers

New insights into metabolites that control aging and disease - Read more at:

A Complete Guide of 𝐀𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 - [PDF Guide] ➡ 𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐟𝐨𝐫 𝐏𝐃𝐅>> https://lnkd.in/eeic7fYi Autoimmune disease testing involves testing for antibodies that attack the body’s healthy #cells and #tissues; it can be done using various tests, including antinuclear antibodies (ANA), C-reactive protein (#CRP), erythrocyte sedimentation rate (#ESR), rheumatoid factor, immunoglobulins, and routine blood tests. These tests diagnose and monitor systemic autoimmune diseases affecting multiple organs or systems or specific autoimmune diseases. The growth of the autoimmune disease #diagnostics market is driven by the increasing prevalence of autoimmune disorders, the growing emphasis on early diagnosis, and the rising awareness regarding autoimmune #diseases. However, difficulties in diagnosing autoimmune diseases restrain the growth of this market. Emerging economies and increasing investments & funding in the autoimmune diseases space are expected to generate growth opportunities for the players in this market. 𝐛𝐲 𝐓𝐞𝐬𝐭 𝐓𝐲𝐩𝐞 ·      Antinuclear Antibodies (ANA) Test ·      Rheumatoid Factor Test ·      Immunoglobulins Test ·      Routine Blood Tests Test ·      C-reactive Protein (CRP) Test ·      Erythrocyte Sedimentation Rate (ESR) Test ·      Other Test Types #AutoimmuneTesting #AutoimmuneAwareness #AutoimmuneDisease #ChronicIllness #AutoimmuneWarrior #DiagnosisJourney #HealthTesting #InvisibleIllness #PatientAdvocacy #KnowYourStatus

Exploring a thought-provoking article penned by Nina Blažević, Dunja Rogic, Stipe Pelajić, Marijana Miler, Goran Glavcic, Valentina Ratkajec, Nikolina Vrkljan, Dejan Bakula, Davor Hrabar and Tajana Pavic, profound insights were uncovered into the pivotal role of YKL-40 (CHI3L1) in inflammatory diseases. Despite lacking enzymatic activity for chitin, YKL-40 plays key roles in apoptosis, inflammation and extracellular matrix dynamics. This comprehensive review highlights YKL-40's emergence as a persuasive biomarker for early diagnosis, prediction and monitoring of various inflammatory conditions. With its involvement across cardiovascular, gastrointestinal, endocrinological and other domains, YKL-40 offers promising avenues for improved disease management. Kudos to all the authors for their valuable contributions to shedding light on YKL-40's significance in inflammation research. This article is a must-read for anyone interested in advancing our understanding of inflammatory diseases. You can access the complete article via the following link: https://lnkd.in/dD2SCSt6 #Inflammation #Biomarkers #YKL40 #Research #Healthcare #Medicine ⚕

Nightingale Health’s mission is to enable disease prevention on a global scale. To advance our mission, we have collaborated with large biobanks like UK Biobank to fuel research on the most common chronic diseases such as type 2 diabetes and heart disease.    To make reviewing research findings from the UK Biobank easy, we have released the full range of associations between Nightingale Biomarkers and hundreds of diseases via a free web tool called Nightingale Biomarker-Disease Atlas: https://lnkd.in/efpudBNP    As an example, the picture from our Atlas shows the associations between heart attack (I21 acute myocardial infarction) and Nightingale Biomarkers. We can see how a high ApoA to ApoB1 ratio and chronic inflammation (GlycA) increase the risk of heart attack while high HDL cholesterols protect from heart attack.    In addition, our biomarker results are available to researchers globally as part of our collaboration with the UK Biobank. Researchers can access the UK Biobank data via their online Research Analysis Platform: https://lnkd.in/dEHXU6mc    Want to receive news about interesting publications in the field of metabolic profiling and projects from scientists with whom Nightingale Health works? Subscribe to our Research News: ngh.site/researchnews 

Many studies suggested that the bile acid-gut microbiota axis played a key role in the development of Inflammatory Bowel Disease (IBD) patients. IBD is a term for conditions (such as: Crohn's disease and ulcerative colitis, but also Symptomatic Uncomplicated Diverticular Disease, SUDD) that are characterized by chronic inflammation of the gastrointestinal tract. There is a complex interaction between host genetic risk factors, environmental factors, and a dysbiotic gut microbiota which combine to effect disease progression. Prolonged inflammation results in damage to the GI tract. Specific bile acid metabolites interact with intestinal epithelial and immune cells to contribute to the inflammatory environment seen in IBD. This suggests that BA may provide a novel therapeutic approach for IBD. Learn more: https://lnkd.in/dC4Ux8vy #IBD #BileAcids #NovelApproaches

Learn how epigenetic studies are leading to new insights into pathophysiology of disease to uncover potential novel avenues for disease diagnosis and therapies. Dr. Sonia Garcia-Calzon describes methylation risk scores and sub-grouping of type 2 diabetes (T2D). Now available on demand, register today!